BONA
15.1.2024 08:05:25 CET | Business Wire | Press release
Bona, a global, sustainably driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, is announcing the launch of its new lacquer, Bona Mega EVO™. This next generation lacquer offers a new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, the lacquer contributes to healthier working conditions with a lower impact on indoor air quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240114100435/en/
Announcing Bona Mega EVO™ a next generation lacquer that offers new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, Bona Mega EVO contributes to healthier working conditions with a lower impact on indoor air quality. (Photo: Business Wire)
Bona Mega EVO™ is the next evolution of Bona Mega, which was first introduced in 1996 and offered an industry-first oxygen crosslinking technology and, at the time, was considered a top choice among flooring contractors for use as a one-component topcoat for wood floors in environments requiring medium to light commercial wear resistance. Bona Mega EVO™ is the next generation that incorporates a completely new and significantly faster technology that is unique to Bona. The self crosslinking occurs entirely within the lacquer without the use of any external components, making it a next generation coating.
“When it comes to performance, Bona Mega EVO™ is an advancement in every way. With the new self crosslinking technology, we have merged the top features from Bona Mega and Bona Mega ONE to create an exceptional product. It stands out from the competition due to its consistently high level of performance. Bona Mega EVO™ is the next step for coating medium- to light-commercial areas and domestic wood floors,” said Thomas Hallberg, Director Product Management Professional EMEA/APAC, Bona AB
Bona Mega EVO’s new self crosslinking technology provides a topcoat that dries quickly, remains clear over time, offers excellent sanding ability, and has VOC levels below 3%. It has high filling abilities, low odour, and excellent scratch, wear, and chemical resistance. With Bona Mega EVO’s fast-drying and quick cure time, the floor can be in use more quickly when compared to other one-component lacquers. This also means that the next topcoat layer can be applied much sooner than with traditional polymer technology.
Bona Mega EVO™ guarantees a uniform colouring of the wood floor even without the use of a primer making it possible to use just one product during the whole process. It has a non-yellowing formula with minimal odour during the application process and dissipates rapidly afterwards.
With VOC levels below 3%, Bona Mega EVO™ fulfills the EMICODE® EC1PLUS certification. Bona continues its work to phase out PFAS, of which Bona Mega EVO is no exception, promoting a safer environment.
About Bona
Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 16 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240114100435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom